Chemotherapy-induced nausea and vomiting is a common adverse effect of chemotherapy in oncology patients, which seriously affects patients’ quality of life and has a direct and obvious negative impact on patients’ emotions. Many patients give up continuing chemotherapy because of nausea and vomiting and lose valuable treatment opportunities. The MAI regimen for soft tissue sarcoma is the most effective first-line regimen, but carries a high risk of emesis, i.e., over 90% of patients experience nausea and vomiting despite prophylactic antiemetic therapy. To achieve maximum protection for patients with CINV, prophylactic antiemetic regimens must be administered prior to the initiation of chemotherapy. Clinical studies have demonstrated that the combination of 5-hydroxytryptamine receptor blockers and glucocorticoids such as dexamethasone can significantly reduce the incidence of nausea and vomiting in chemotherapy patients and is currently one of the standard options for post-chemotherapy antiemetic therapy; 3. -1 receptor blockers in combination with 5-hydroxytryptamine receptor blockers and glucocorticoids such as dexamethasone can reduce the risk of CINV by 20% and reduce the difference between the incidence of CINV in men and women.